查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1830305

HIV疫苗市場（依疫苗類型、技術、給藥途徑、最終用戶和分銷管道）－2025-2032年全球預測

HIV Vaccines Market by Vaccine Type, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，HIV 疫苗市場規模將成長至 25.5237 億美元，複合年成長率為 13.29%。

主要市場統計數據
基準年2024年 9.4005億美元
預計2025年 10.6416億美元
預測年份：2032年 2,552,370,000美元
複合年成長率（%） 13.29%

簡明指南：科學、監管和營運力量如何融合，共同影響愛滋病毒疫苗的開發和計畫重點

HIV疫苗研發在免疫學、病毒學和全球公共衛生策略的交叉領域中發揮關鍵作用。抗原設計、遞送平台和免疫調節技術的最新科學進展正在重新定義技術可實現性，同時法律規範和臨床試驗設計也不斷適應新的模式。包括公共衛生機構、學術聯盟和私人開發商在內的相關人員正在應對複雜的科學權衡、不斷變化的社會期望以及對永續生產和分銷方法的需求所塑造的局面。

本執行摘要旨在總結最重要的進展，並明確其對決策者的策略意義。它揭示了不斷變化的平台技術偏好、監管調整和地緣政治動態如何影響各個開發組合的優先事項。摘要也闡明了給藥途徑選擇、最終用戶需求和分銷管道如何與技術選擇和臨床策略相互交織。透過梳理這些因素，引言為切實可行的見解奠定了基礎，這些見解有助於研究、臨床和商業相關人員確定專案優先順序、建立夥伴關係關係並產業計畫。

平台多樣化、給藥途徑最佳化、監管協調和協作模式如何改變愛滋病毒疫苗策略

HIV疫苗領域正在經歷一系列變革，這些變革時期正在重新定義研究策略、投資重點和合作架構。首先，平台多樣化正在推動平行發展路徑。雖然重組蛋白和類病毒顆粒構建體等傳統方法對於特定免疫譜仍然重要，但基於核苷酸的平台（例如常規mRNA和自擴增mRNA）因其快速的設計週期和靈活的抗原呈現方式，正重新引起人們的關注。同時，病毒載體和胜肽策略也在不斷改進，以提高安全性、反應持久性和靶向細胞免疫。

其次，免疫原設計與給藥途徑選擇的整合正成為臨床策略的關鍵決定因素。雖然肌肉注射仍然是許多候選藥物的預設給藥方式，但鼻內和皮下途徑由於其在黏膜免疫和節省劑量方面的優勢而正在被重新考慮。第三，監管機構越來越重視一致的終點、自適應試驗設計和真實世界數據的整合。最後，共同研究模式也在改變。多利益相關者相關利益者、官民合作關係和新型授權安排正在成為平衡科學風險、資本強度和國際准入目標的標準機制。總的來說，這些轉變擴展了專案領導者可行策略的範圍，同時也提升了綜合技術、監管和商業規劃的重要性。

評估 2025 年關稅變化如何重塑整個 HIV 疫苗價值鏈的採購、製造足跡和聯合生產策略

2025年左右宣布的關稅政策變化，為疫苗供應鏈、籌資策略和跨境合作帶來了新的考量。某些原料、零件和成品的關稅上調，可能會影響生產基地的成本競爭力，並影響疫苗成品和關鍵中間體的產地決策。這些動態提升了供應鏈透明度和策略採購的重要性，以減少對關鍵試劑和耗材單一國家供應商的依賴。

除了直接的成本影響外，關稅波動還會導致營運摩擦，延長前置作業時間並使庫存計劃變得複雜。製造商和經銷商正在採取多種應對措施，包括建立多元化供應商網路、提昇在岸或近岸製造能力，以及重新協商長期供應協議以納入關稅意外事件。採購團隊還必須調整合約措辭，以應對海關合規性、關稅減免條款以及產品跨越多個司法管轄區時可能出現的監管差異。

重要的是，關稅會影響合作。研究合作和製造業夥伴關係可能會強調本地生產和技術轉讓，以避免跨國成本並與國家產業政策保持一致。政策制定者和業界都在評估關稅制度如何影響公平准入目標，並越來越關注在維持可負擔性的同時支持具有韌性的製造業生態系統的合作機制。

綜合細分洞察，將疫苗類型、平台技術、給藥途徑、最終用戶動態和分銷選項與策略決策聯繫起來

細緻地審視細分市場，可以發現產品策略、技術選擇、給藥途徑、用戶需求和通路如何相互作用，從而決定開發和商業化的重點。在評估疫苗類型時，預防方法包括傳統的去活化病毒、減毒活疫苗、重組蛋白疫苗和類病毒顆粒候選物，每種疫苗都有不同的免疫抗原性特徵和生產影響。技術選擇涵蓋DNA、mRNA、胜肽和病毒載體平台，其中mRNA類別本身又分為傳統的mRNA構建體和旨在增強抗原表達和給藥效率的自擴增mRNA。

給藥途徑（肌肉注射、鼻腔注射、皮下注射）既影響免疫接種的原理，也影響部署的營運物流，進而影響低溫運輸需求和管理培訓。最終用戶細分揭示了診所、醫院、製藥公司和研究機構的不同需求。在診所內部，醫院附屬診所和獨立診所之間的差異會影響採購管道和病患流程設計，而私人醫院和公立醫院的採購框架和預算週期也有所不同。分銷管道的選擇——直銷、線上銷售或零售藥局——進一步決定了醫療服務提供者的參與模式和病患獲取途徑。這些細分維度共同構成了開發人員和專案經理的多維決策矩陣，必須在科學、監管和商業性時間表上進行協調。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和戰略要務將決定監管協調和部署準備情況

區域動態對於愛滋病毒疫苗研發、監管策略和部署的策略規劃至關重要。美洲的監管環境擁有先進的臨床試驗基礎設施和多元化的支付方組合，鼓勵循序漸進的臨床路徑，並與學術中心和私人製造商建立合作夥伴關係。由於各國的智慧財產權框架和採購機制各不相同，跨境策略通常優先考慮與國家監管機構和支付方進行早期接觸，以協調證據包和報銷預期。

歐洲、中東和非洲地區情況複雜，監管協調工作與生產能力和醫療保健可近性的巨大差異並存。該地區亟需制定靈活的發展計劃，以適應不同的臨床試驗人群，並整合技術轉移要素，從而建立永續的本地能力。與區域公共衛生機構和多邊採購組織的合作通常對於確保廣泛的可及性和協調部署重點至關重要。

亞太地區展現出一系列能力，從高產量的生產中心到快速現代化的監管體系和廣泛的臨床試驗網路。開發商通常會尋求區域生產協議或戰略許可，以利用生產規模並滿足當地監管要求。在所有地區，當地相關人員關係、監管透明度和生產韌性仍然是候選疫苗從開發到分銷快速有效推進的關鍵決定因素。

領先的研究、研發和製造合作夥伴如何建構產品組合、合作和製造方法以獲得轉換優勢

HIV疫苗生態系統中的領先研究機構正在不斷改進其產品組合和夥伴關係方式，以應對科學進步和不斷變化的營運限制。公共研究機構持續提供基礎免疫學見解，為轉化項目提供資訊；而製藥和生物技術開發商則將新型抗原設計與先進的遞送平台相結合，以最佳化免疫的持久性和廣度。策略合作通常將平台專家與提供臨床試驗基礎設施和本地生產能力的組織配對，從而加快規模化進程並提高試驗入組效率。

整合模組化製造能力和靈活CMC（化學、製造和控制）流程的公司往往能夠更順利地管理臨床轉換。投資低溫運輸創新、品質源自於設計製造和可擴展分析的公司正在增強其支持跨區域擴張的能力。同時，提供端到端服務和監管經驗的受託製造廠商(CDMO) 對專案進度至關重要，尤其是在需要區域內製造和技術轉移的情況下。在整個生態系統中，競爭優勢在於那些將科學新穎性與營運執行、監管前瞻性和協作敏捷性相結合的營業單位。

專案領導者應採取切實可行的策略行動，平衡平台可選性、供應鏈彈性、監管參與度和公平准入夥伴關係

產業領導者應將近期戰術性行動與策略藍圖結合，以平衡科學風險、營運韌性和可及性目標。早期投資組合優先考慮平台無關性，以保持重組蛋白、類病毒顆粒、核苷酸構建體和病毒載體的多樣性。同時，他們投資於特定模式的下游能力，例如製劑科學、低溫運輸物流和給藥途徑最佳化，以減輕後期轉化阻力。

透過實現關鍵投入品供應商多元化、探索近岸外包和區域製造夥伴關係關係以及在採購合約中納入關稅應急條款，增強供應鏈彈性。透過及早與監管機構接觸、推行統一的終端和自適應測試框架來加強監管策略，這有助於在保持強力的安全監督的同時加快證據生成。此類模式應包括清晰的管治、智慧財產權管理策略以及協調公共和私人相關人員之間獎勵的共用上市計劃。此類模式應包括清晰的管治、智慧財產權管理策略以及協調公共和私人相關人員之間獎勵的共用上市計劃。

我們透明且可重複的調查方法將主要專家訪談與次要科學和監管證據相結合，以提供可行的項目見解

本報告整合了主要和次要訊息，建構了嚴謹且可重複的HIV疫苗發展態勢。主要資訊包括對臨床研究人員、生產專家、監管顧問和採購相關人員的結構化訪談，以及來自積極應對開發和規模化挑戰的後期專案經理的匿名定性回饋。次要資訊則參考了同行評審文獻、官方監管指南、臨床試驗註冊中心和會議報告，以分析科學趨勢並檢驗轉化假設。

我們優先考慮分析方法的透明度，記錄關於技術性能、供應鏈約束和監管途徑的假設，並透過敏感度檢驗來探索平台採用和生產策略的替代方案。在適用的情況下，我們的結論強調基於證據的相關性，而非推測性預測。我們的調查方法支援按技術、給藥途徑和地區進行自訂篩選，為需要針對合作、採購和臨床策略制定進行重點分析的決策者提供夥伴關係的、可提取的洞察。

整合技術、監管、供應鏈和區域方面的考慮，確定將愛滋病毒疫苗創新轉化為可用解決方案的現實途徑

總而言之，HIV疫苗領域的特點是技術多樣性加速發展、監管格局不斷演變，以及對供應鏈和區域部署現狀的日益關注。保持平台靈活性、投資特定給藥途徑的營運能力，並積極與區域相關人員合作的開發商，將更有能力將科學進步轉化為可行的產品。不斷變化的關稅和貿易政策凸顯了彈性採購和生產策略的重要性，而市場區隔和區域動態則凸顯了需要根據最終用戶需求和分銷通路現狀制定量身定做的方案。

從前景光明的免疫原到廣泛可用的疫苗，需要一個涵蓋科學、生產、監管和商業性途徑的綜合計劃。策略夥伴關係、模組化生產方法和早期監管對話將繼續加速專案進展。最終，成功的專案將技術創新與切實可行的實施計劃相結合，這些計劃以公平獲取為中心，同時預見政策和物流的限制。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 基於 mRNA 的 HIV 候選疫苗的進展展現出更廣泛的免疫反應和持久的保護
  • 開發鑲嵌抗原製劑以針對多種愛滋病毒株並提高覆蓋率
  • 將廣泛中和抗體誘導方法整合到下一代愛滋病毒疫苗研究管道中
  • 採用奈米顆粒遞送系統提高抗原穩定性和標靶免疫激活
  • 在撒哈拉以南非洲高發生率地區啟動預防性愛滋病毒疫苗大規模臨床試驗
  • 生物技術與學術合作加速愛滋病毒候選疫苗的開發與測試
  • 新的法規結構有利於加速核准具有良好安全性的有前景的愛滋病毒候選疫苗

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. HIV疫苗市場（依疫苗類型）

  • 預防
    • 去活化病毒
    • 減毒活病毒
    • 重組蛋白
    • 類病毒顆粒
  • 治療

9. HIV疫苗市場（依技術）

  • DNA
  • mRNA
    • 常規mRNA
    • 自我擴增的mRNA
  • 胜肽
  • 病毒載體

第10章 HIV 疫苗市場（依給藥途徑）

  • 肌肉注射
  • 鼻內
  • 皮下

第 11 章 HIV 疫苗市場（以最終用戶分類）

  • 診所
    • 醫院附設診所
    • 獨立診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 製藥公司
  • 研究機構

第 12 章：愛滋病毒疫苗市場（按分銷管道）

  • 直銷
  • 網上銷售
  • 零售藥局

13. HIV疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章：愛滋病毒疫苗市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國愛滋病疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Johnson & Johnson, Inc.
    • Moderna, Inc.
    • BioNTech SE
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novavax, Inc.
    • CureVac NV
    • Bavarian Nordic GmbH
Product Code: MRR-4312A385A507

The HIV Vaccines Market is projected to grow by USD 2,552.37 million at a CAGR of 13.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 940.05 million
Estimated Year [2025] USD 1,064.16 million
Forecast Year [2032] USD 2,552.37 million
CAGR (%) 13.29%

Concise orientation to the converging scientific, regulatory, and operational forces reshaping HIV vaccine development and program priorities

HIV vaccine development occupies a pivotal role at the intersection of immunology, virology, and global public health strategy. Recent scientific advances in antigen design, delivery platforms, and immune modulation techniques have reframed what is technically achievable, while regulatory frameworks and clinical trial designs continue to adapt to novel modalities. Stakeholders across public health institutions, academic consortia, and private developers are navigating a landscape shaped by complex scientific trade-offs, evolving public expectations, and the need for sustainable manufacturing and distribution approaches.

This executive summary aims to synthesize the most consequential developments and to surface strategic implications for decision-makers. It clarifies how shifts in platform technology preferences, regulatory alignment, and geopolitical dynamics are influencing priorities across development portfolios. The summary also highlights how route of administration choices, end-user requirements, and distribution channels intersect with technology selection and clinical strategy. By framing these factors together, the introduction sets the stage for actionable insight that supports program prioritization, partnership formation, and operational planning across research, clinical, and commercial stakeholders.

How platform diversification, administration route optimization, regulatory harmonization, and collaborative models are jointly transforming HIV vaccine strategies

The HIV vaccine landscape is undergoing several transformative shifts that are redefining research strategies, investment priorities, and the architecture of collaboration. First, platform diversification is driving parallel development pathways: while traditional approaches like recombinant protein and virus-like particle constructs retain importance for certain immune profiles, nucleotide-based platforms such as conventional mRNA and self-amplifying mRNA are catalyzing renewed interest due to their rapid design cycles and flexible antigen presentation. At the same time, viral vectors and peptide strategies continue to be refined to improve safety, durability of response, and targeted cellular immunity.

Second, integration of immunogen design with delivery route selection is emerging as a critical determinant of clinical strategy. Intramuscular administration remains the default for many candidates, but intranasal and subcutaneous routes are being reexamined for mucosal immunity and dose-sparing advantages respectively. Third, regulatory agencies are increasingly emphasizing harmonized endpoints, adaptive trial designs, and real-world data integration, which accelerates translational pathways but requires robust post-authorization evidence plans. Finally, collaboration models are shifting: multi-stakeholder consortia, public-private partnerships, and novel licensing arrangements are becoming standard mechanisms to balance scientific risk, capital intensity, and global access objectives. These shifts collectively expand the set of feasible strategies for program leaders while raising the premium on integrated technical, regulatory, and commercial planning.

Assessing how 2025 tariff shifts are reshaping sourcing, manufacturing footprints, and collaborative production strategies across the HIV vaccine value chain

Tariff policy changes announced in and around 2025 have introduced a new set of considerations for vaccine supply chains, procurement strategies, and cross-border collaboration. Increased duties on certain raw materials, components, and finished products can impact the cost competitiveness of manufacturing footprints and influence decisions about where to site production for finished vaccines or key intermediates. These dynamics amplify the importance of supply chain visibility and of strategic sourcing that reduces dependence on single-country suppliers for critical reagents and consumables.

Beyond direct cost effects, tariff shifts can create operational frictions that extend lead times and complicate inventory planning. Manufacturers and distributors respond by diversifying supplier networks, increasing onshore or nearshore manufacturing capacity, and renegotiating long-term supply agreements to incorporate tariff contingencies. Procurement teams must also adjust contracting language to address customs compliance, tariff mitigation clauses, and potential regulatory variances that arise when products cross multiple jurisdictions.

Importantly, tariffs can influence collaborative structures: research collaborations and manufacturing partnerships may emphasize in-region production and technology transfer to avoid cross-border cost penalties and to align with national industrial policies. Policymakers and industry alike are assessing how tariff instruments affect equitable access objectives, with a growing emphasis on cooperative mechanisms that preserve affordability while supporting resilient manufacturing ecosystems.

Integrated segmentation insights that connect vaccine type, platform technology, administration route, end-user dynamics, and distribution choices to strategic decision-making

A nuanced view of segmentation reveals how product strategy, technology choice, administration route, user needs, and distribution pathways interact to determine development and commercialization priorities. When evaluating vaccine type, preventive approaches encompass traditional inactivated virus, live attenuated constructs, recombinant protein assets, and virus-like particle candidates, each offering distinct immunogenicity profiles and manufacturing implications; therapeutic candidates pursue different endpoints and patient cohorts, influencing clinical design and long-term engagement with healthcare systems. Technology selection spans DNA, mRNA, peptide, and viral vector platforms, where the mRNA category itself differentiates between conventional mRNA constructs and self-amplifying mRNA that aim to enhance antigen expression and dose efficiency.

Route of administration considerations-intramuscular, intranasal, and subcutaneous-affect both the immunological rationale and the operational logistics of deployment, shaping cold chain requirements and administration training. End-user segmentation highlights divergent requirements from clinics, hospitals, pharmaceutical companies, and research institutes; within clinics, the distinction between hospital-affiliated clinics and standalone clinics informs procurement channels and patient flow design, while private and public hospitals exhibit different purchasing frameworks and budgetary cycles. Distribution channel choices, including direct sales, online sales, and retail pharmacies, further determine engagement models with healthcare providers and patient access pathways. Together, these segmentation dimensions create a multidimensional decision matrix for developers and program managers that must be reconciled across scientific, regulatory, and commercial timelines.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory alignment and deployment readiness

Regional dynamics are central to strategic planning for HIV vaccine development, regulatory strategy, and deployment. In the Americas, regulatory jurisdictions exhibit a mix of advanced clinical trial infrastructure and diverse payer landscapes, which encourages staged clinical pathways and partnerships with both academic centers and commercial manufacturers. Intellectual property frameworks and procurement mechanisms vary across countries, so cross-border strategies often prioritize early engagement with national regulators and payers to align evidence packages with reimbursement expectations.

Europe, Middle East & Africa presents a complex mosaic where regulatory harmonization initiatives coexist with significant variability in manufacturing capacity and healthcare access. This region emphasizes the need for flexible development plans that accommodate diverse clinical trial populations and that integrate technology transfer elements to build sustainable local capacity. Engagement with regional public health bodies and multilateral procurement entities is often essential to ensure broad access and to coordinate rollout priorities.

Asia-Pacific demonstrates a range of capabilities from high-volume manufacturing hubs to rapidly modernizing regulatory systems and extensive clinical trial networks. Developers frequently pursue regional manufacturing arrangements and strategic licensing to leverage production scale and to navigate national regulatory requirements. Across all regions, local stakeholder relationships, regulatory clarity, and manufacturing resilience remain key determinants of how quickly and effectively vaccine candidates progress from development to delivery.

How leading research institutes, developers, and manufacturing partners are structuring portfolios, collaborations, and manufacturing approaches to gain translational advantage

Leading organizations across the HIV vaccine ecosystem are evolving their portfolios and partnership approaches in response to scientific progress and shifting operational constraints. Public research institutions continue to supply fundamental immunology insights that feed translational programs, while pharmaceutical and biotech developers are combining novel antigen designs with advanced delivery platforms to optimize immune durability and breadth. Strategic collaborations frequently pair platform specialists with organizations that provide clinical trial infrastructure or regional manufacturing capacity, enabling faster scale-up and more efficient study enrollment.

Companies that integrate modular manufacturing capabilities and flexible CMC (chemistry, manufacturing, and controls) processes tend to manage clinical transitions more smoothly. Firms investing in cold chain innovation, quality-by-design manufacturing, and scalable analytics strengthen their ability to support multi-regional rollouts. Meanwhile, contract development and manufacturing organizations (CDMOs) that offer end-to-end services and regulatory experience are increasingly central to program timelines, especially where in-region production or technology transfer is required. Across the ecosystem, competitive advantage accrues to entities that align scientific novelty with operational execution, regulatory foresight, and collaborative agility.

Practical strategic actions for program leaders to balance platform optionality, supply chain resilience, regulatory engagement, and equitable access partnerships

Industry leaders should align near-term tactical actions with a strategic roadmap that balances scientific risk, operational resilience, and access objectives. Prioritize platform agnosticism in early-stage portfolios to preserve optionality between recombinant protein, virus-like particles, nucleotide-based constructs, and viral vectors; this approach allows programs to pivot as clinical data clarifies correlates of protection and durability signals. Simultaneously, invest in modality-specific downstream capabilities such as formulation science, cold chain logistics, and route-of-administration optimization to reduce late-stage translational friction.

Strengthen supply chain resilience by diversifying suppliers for critical inputs, exploring nearshoring or regional manufacturing partnerships, and embedding tariff contingency clauses in procurement contracts. Enhance regulatory strategy by engaging regulators early and pursuing harmonized endpoints and adaptive trial frameworks that support accelerated evidence generation while maintaining robust safety oversight. Finally, develop partnership models that enable technology transfer, local capacity building, and equitable access arrangements; such models should include clear governance, IP management strategies, and shared go-to-market plans that align incentives across public and private stakeholders. These actions collectively reduce program risk and increase the likelihood that promising candidates can progress efficiently from clinical proof-of-concept to broad availability.

Transparent, reproducible research methodology combining primary expert interviews and secondary scientific and regulatory evidence to inform actionable program insights

This report synthesizes primary and secondary inputs to construct a rigorous, reproducible view of the HIV vaccine landscape. Primary inputs include structured interviews with clinical investigators, manufacturing experts, regulatory advisors, and procurement stakeholders, combined with anonymized qualitative feedback from late-stage program managers who are actively navigating development and scale-up challenges. Secondary inputs draw on peer-reviewed literature, public regulatory guidance, clinical trial registries, and conference disclosures to triangulate scientific trends and to validate translational assumptions.

Analysis prioritizes methodological transparency: assumptions about technology performance, supply chain constraints, and regulatory pathways are documented, and sensitivity checks explore alternative scenarios for platform adoption and manufacturing strategies. Where applicable, conclusions emphasize evidence-based linkages rather than speculative projections. The methodology supports custom filtering by technology, route of administration, and region, enabling tailored extractable insights for decision-makers who require focused analysis for partnerships, procurement, or clinical strategy development.

Synthesis of technology, regulatory, supply chain, and regional considerations that define the practical pathways to translating HIV vaccine innovation into accessible solutions

In conclusion, the HIV vaccine landscape is characterized by accelerating technological diversity, evolving regulatory expectations, and heightened attention to supply chain and regional deployment realities. Developers who maintain platform flexibility, invest in operational capabilities that align with chosen administration routes, and proactively engage with regional stakeholders will be better positioned to translate scientific advances into deliverable products. Tariff and trade policy shifts underscore the importance of resilient sourcing and manufacturing strategies, while segmentation and regional dynamics highlight the need for tailored approaches that reflect end-user requirements and distribution channel realities.

The path from promising immunogen to widely accessible vaccine requires integrated planning across science, manufacturing, regulation, and commercial pathways. Strategic partnerships, modular manufacturing approaches, and early regulatory dialogue will continue to accelerate program progression. Ultimately, successful programs will be those that pair technical innovation with pragmatic execution plans that anticipate policy and logistical constraints while centering equitable access objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mRNA-based HIV vaccine candidates demonstrating broader immune responses and durable protection
  • 5.2. Development of mosaic antigen formulations aiming to target multiple HIV strains with enhanced coverage
  • 5.3. Integration of broadly neutralizing antibody inducement approaches into next generation HIV vaccine research pipelines
  • 5.4. Adoption of nanoparticle delivery systems to improve antigen stability and targeted immune activation in HIV vaccines
  • 5.5. Initiation of large scale clinical trials focusing on preventative HIV vaccines in high incidence regions of sub-Saharan Africa
  • 5.6. Collaboration between biotechnology firms and academic institutions to accelerate HIV vaccine candidate development and testing
  • 5.7. Emerging regulatory frameworks facilitating accelerated approval pathways for promising HIV vaccine candidates with strong safety profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Vaccines Market, by Vaccine Type

  • 8.1. Preventive
    • 8.1.1. Inactivated Virus
    • 8.1.2. Live Attenuated Virus
    • 8.1.3. Recombinant Protein
    • 8.1.4. Virus-Like Particle
  • 8.2. Therapeutic

9. HIV Vaccines Market, by Technology

  • 9.1. Dna
  • 9.2. Mrna
    • 9.2.1. Conventional Mrna
    • 9.2.2. Self-Amplifying Mrna
  • 9.3. Peptide
  • 9.4. Viral Vector

10. HIV Vaccines Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intranasal
  • 10.3. Subcutaneous

11. HIV Vaccines Market, by End User

  • 11.1. Clinics
    • 11.1.1. Hospital-Affiliated Clinics
    • 11.1.2. Standalone Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. HIV Vaccines Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Online Sales
  • 12.3. Retail Pharmacies

13. HIV Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. HIV Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. HIV Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson, Inc.
    • 16.3.2. Moderna, Inc.
    • 16.3.3. BioNTech SE
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Sanofi S.A.
    • 16.3.6. Merck & Co., Inc.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Novavax, Inc.
    • 16.3.9. CureVac N.V.
    • 16.3.10. Bavarian Nordic GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 348. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 349. ASEAN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 350. ASEAN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 351. ASEAN HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 352. ASEAN HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 353. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 354. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 355. ASEAN HIV VACC